Predict your next investment

HEALTHCARE | Medical Devices & Equipment / Surgical Devices
neuropace.com

See what CB Insights has to offer

Founded Year

1997

Stage

IPO | IPO

Total Raised

$278.05M

Date of IPO

4/22/2021

Market Cap

0.53B

Stock Price

17.42

About NeuroPace

NeuroPace (NASDAQ: NPCE) designs, develops, manufactures, and markets implantable devices for the treatment of neurological disorders by responsive brain stimulation. The company's initial focus is the treatment of epilepsy, a debilitating neurological disorder affecting approximately one percent of the population worldwide. An estimated 30-40 percent of the 50 million people worldwide (including more than 3 million Americans) experience uncontrolled seizures. In addition to treating epilepsy, responsive neurostimulation holds the promise of treating several other disabling medical disorders that impact the quality of life for millions of patients around the world.

NeuroPace Headquarter Location

455 N Bernardo Avenue

Mountain View, California, 94043,

United States

866-726-3876

Latest NeuroPace News

Implantable Infusion Pumps Global Markets Report 2020-2030: Focus on Patient-Controlled Analgesia (PCA), Enteral, Insulin, Elastomeric, Syringe Pumps - ResearchAndMarkets.com

Sep 16, 2021

Major players in the implantable infusion pumps market are Medtronic, Boston Scientific Corporation, Nevro Corporation, Cyberonics, Baxter, B. Braun Melsungen AG, Fresenius Kabi AG, Smiths Medical, Terumo Corporation and Neuropace. The global implantable infusion pumps market is expected to grow from $13.32 billion in 2019 to $16.22 billion in 2020 at a compound annual growth rate (CAGR) of 21.75%. The growth is mainly due to the COVID-19 outbreak that has increased the demand for intravenous infusion pumps to treat the affected patients. The market is then expected to stabilize and reach $16.98 billion in 2023 from 2021 at a CAGR of 1.55%. The implantable infusion pumps market consists of sales of implantable infusion pumps and related services by entities (organizations, sole traders and partnerships) that manufacture implantable infusion pumps. An implantable infusion pump is a small device that is put beneath the skin during the operation. The pump delivers the liquid pain medication to a different part of the body through a long, flexible tube called the catheter. The implantable infusion pumps market by type into patient-controlled analgesia (PCA) pumps; enteral pumps; insulin pumps; elastomeric pumps; syringe pumps; others and by applications into oncology; pediatrics/neonatology; gastroenterology; hematology; diabetes; others. In September 2019, Baxter International Inc., a global medical products company, acquired Cheetah Medical for $190 million. This deal is expected to expand Baxter's product portfolio and strengthen the company's clinical outcomes with patient monitoring technology. Cheetah Medical is a US-based device company offering non-invasive cardiac output and hemodynamic monitoring devices including infusion pumps. The safety concern regarding implantable infusion pumps is a key factor hampering the growth of the implantable infusion pumps market. The magnetic resonance (MR) system can be useful in the diagnosis of a wide range of conditions and diseases, but the MRI setting poses a risk factor for patients with implantable infusion pumps. An MRI examination can influence the programming or functionality of an infusion pump, even if specific requirements have been met. Therefore, the safety concerns regarding implantable infusion pumps is expected to limit the growth of the implantable infusion pumps market. Companies in the implantable infusion pump market are increasingly focusing on developing smart infusion pumps. The use of wireless technology in the health monitoring devices is increasing, which enhances the ease of usage, connectivity and data analysis. The integration of wireless technology allows the transfer of data from the device to a smartphone or a wireless device through Bluetooth or cellular connection for data processing and then to display the results, which can be used for further study and to check the health condition of the individual. Software platforms are being developed that allow patient monitoring and reduce human error. The increased prevalence of people with chronic pain, cancer and diabetes is expected to drive the demand for implantable infusion pumps, as these pumps are commonly used to deliver pharmaceutical drugs during the treatment of these diseases. Chronic illnesses and disorders are on the rise around the world, as the aging population and shifts in social behavior lead to a gradual increase in these diseases. In diseases such as chronic arachnoiditis, which is a condition where one of the membranes surrounding the spinal cord swells, implantable infusion pumps deliver lower dosages of drugs and tend to provide more efficient pain relief. The prevalence of chronic diseases is expected to increase by 57% by 2020, according to the World Health Organization. Therefore, the rise in the prevalence of chronic diseases is expected to drive the growth of the implantable infusion pumps market. Key Topics Covered:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing NeuroPace

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

NeuroPace is included in 6 Expert Collections, including Smart Money VCs (2017-2019).

S

Smart Money VCs (2017-2019)

6,297 items

We crunched the data to identify the 24 VC firms with the best combination of portfolio valuations and investment outcomes.

G

Game Changers 2018

70 items

N

Neuroscience

2,144 items

Companies developing products that monitor, analyze, protect, or otherwise influence the structure/function of the nervous system.

M

Medical Devices

11,549 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. Excludes CDMOs/CMOs. *Columns updated as regularly as possible.

B

Bioelectronics

1,098 items

Companies developing/using technology aimed at detecting, interpreting, interrupting, eliciting, or redirecting electrical signals within the body

D

Digital Health

10,285 items

Companies using/incorporating digital tech into health, wellness, and life science offerings. Includes cos operating within the hc, consumer health, and life science industries + tech vendors catering to them. Excludes cos exclusively focused on fitness/sports & performance

NeuroPace Patents

NeuroPace has filed 90 patents.

The 3 most popular patent topics include:

  • Neurophysiology
  • Neurological disorders
  • Neurotechnology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/17/2017

7/20/2021

Neurotechnology, Neurological disorders, Electrotherapy, Implants (medicine), Neuroprosthetics

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

11/17/2017

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

7/20/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Neurotechnology, Neurological disorders, Electrotherapy, Implants (medicine), Neuroprosthetics

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

NeuroPace Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

NeuroPace Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.